Paclitaxel Magnetic Liposomes Preparation And Animal Empirical Study

Objectives: (1) To prepare paclitaxel magnetic liposomes. (2) To study the response of paclitaxel magnetic liposomes to the magnetite both out of and within the body, investigated the biological distribution of the paclitaxel magnetic liposomes in the mice .(3) To evaluate the efficacy of this kind of chemotherapy against mice model of Lewis lung cancer.Methods:(1) Paclitaxel magnetic liposomes were prepared by the film ultrasound method. (2) Paclitaxel in magnetic liposomes and tissue distribution were quantified by highperformance liquid chromatography (HPLC). (3) The Lewis lung cancer cell strain were inoculated subcutaneously of the C57BL/6 mice to set up the animal models of lung cancer. (4)48 mice were allocated into six groups randomly,each group 8 mice, group A: Sodium Chloride only; group B: Paclitaxel Injection; group C:paclitaxel liposomes; group D: magnetic liposomes without paclitaxel; group E: paclitaxel magnetic liposomes without magnetic fields; group F: paclitaxel magnetic liposomes with magnetic fields. All mice were sacrificed on day 12 after various interventions. The curative effect were analysised.Results: (1) We obtained the paclitaxel magnetic liposomes with good appearance. The size of particles was about 600-800nm. The encapsulation rate was above 90%. (2) Paclitaxel magnetic liposomes has a good response to the magnetite both out of and within the body.Administration of paclitaxel magnetic liposomes under magnetic field could be used to deliver paclitaxel effectively to thetargeted site. (3) Treatment with paclitaxel magnetic liposomes via intravenous administration under magnetic force showed significant greater anticancer activity than any other modalitity.Conclusion: The present results suggested that paclitaxel magnetoliposomes could be used to deliver paclitaxel effectively to the tumor with a permanent magnet. This new treatment could effectively control the tumor growth. Our study indicated that magnetic liposome, as an carrier of anticancer drug, had a wide window of opportunity to achieve even...